In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to EHRA Ivory (& above) Members, Fellows of the ESC and Young combined Members

Long term experience of the efficacy and safety of the transseptal endocardial left ventricular lead implantation - An alternative technique in cases of failed cardiac resynchronization therapy

Session Rapid Fire 5: improving the response to cardiac resynchronization therapy: emerging technologies

Speaker Laszlo Alajos Geller

Congress : EHRA 2019

  • Topic : arrhythmias and device therapy
  • Sub-topic : Cardiac Resynchronization Therapy
  • Session type : Rapid Fire Abstracts
  • FP Number : 925

Authors : L A Geller (Budapest,HU), Z Sallo (Budapest,HU), L Molnar (Budapest,HU), T Tahin (Budapest,HU), SZ Szilagyi (Budapest,HU), P Abraham (Budapest,HU), N Szegedi (Budapest,HU), E Zima (Budapest,HU), A Apor (Budapest,HU), AI Nagy (Budapest,HU), EE Ozcan (Budapest,HU), KV Nagy (Budapest,HU), SZ Herczeg (Budapest,HU), B Merkely (Budapest,HU)


L A Geller1 , Z Sallo1 , L Molnar1 , T Tahin1 , SZ Szilagyi1 , P Abraham1 , N Szegedi1 , E Zima1 , A Apor1 , AI Nagy1 , EE Ozcan1 , KV Nagy1 , SZ Herczeg1 , B Merkely1 , 1Semmelweis University, Cardiovascular Center - Budapest - Hungary ,


Introduction: CRT implantation is a gold standard therapy in heart failure patients with left bundle branch block, however, transvenous left ventricular (LV) lead positioning might be challenging or in some cases impossible.
Objectives: The aim of this study was to investigate the effectiveness and safety of transseptal endocardial left ventricular lead implantation (TELVLI) in heart failure patients, and evaluate the long-term follow-ups of the patients.
Methods: TELVLI was performed in 53 patients (44 men, 69±7 years, NYHA III-IV stage) between 2007 and 2018. Intracardiac ultrasound was used to guide the transseptal puncture (TP) in 27 pts. In 35 cases, the TP was performed via the femoral vein, and in the other 18 cases, the TP and also the LV lead placement were both performed via the subclavian vein. The site of the puncture was dilated with a 6mm (the first 3 pts), later with an 8 mm balloon (50 pts). After the puncture of the left subclavian vein, an electrophysiological (EP) deflectable CS catheter or ablation catheter was introduced into the CS sheath. The CS catheter was used to reach the left atrium and after it the left ventricle through the dilated TP hole. The site of the latest activation was mapped with the deflectable EP catheter. At the latest LV activation site 65 cm active fixation bipolar lead was screwed into the LV wall, at the site of the latest activation.
Results: The lead was fixed in the left ventricle in all cases with good pacing threshold (0,82±0,5 V;0,4 ms). Puncture complication, pericardial effusion was not observed. Because of intraoperatively started anticoagulation, pocket hematoma was observed in three (5%) and needed evacuation in one case (2%). Follow-up (FU) was longer than one month in 53 patients [median 29 (IQR 9-40) months]. Significant improvement of NYHA was observed in all but one case (98%), the 6-month control LV EF was 30% (IQR 27-33%) vs. 36% (IQR 32-41 %). Early lead dislocation was noticed in three cases (5%), reposition was performed using the original puncture site in all cases. Explantation of the system was necessary because of pocket infection in four cases (8%), in three of these cases, TELVLI was carried out successfully 3 months later, in one patient 22 months later. All patients were maintained on anticoagulation therapy with INR between 2.5-3. Three thromboembolic complications (2 non-disabling stroke – 4%, 1 TIA – 2%) were noticed during the FU. 28 patients died during the FU in average 15 months after the implantation. Conclusion: TELVLI approach seems to be a very promising alternative technique when transvenous implantation could not be applied. Long-term follow-ups proved a long-term positive effect on LV EF. The stroke rate is similar to the CHF patient’s historical data (3,5-5% during 5 years), however further investigations could clarify the potential role of NOAC treatment in the life-long anticoagulation therapy of these patients.

Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are